Financials data is unavailable for this security.
View more
Year on year Kobayashi Pharmaceutical Co Ltd had little change in net income (from 20.02bn to 20.34bn) despite revenues that grew 4.33% from 166.26bn to 173.46bn. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 32.88% to 33.66%.
| Gross margin | 53.89% |
|---|---|
| Net profit margin | 6.03% |
| Operating margin | 7.53% |
| Return on assets | 3.91% |
|---|---|
| Return on equity | 4.86% |
| Return on investment | 4.69% |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at Kobayashi Pharmaceutical Co Ltd fell by 19.79bn. However, the company earned 18.36bn from its operations for a Cash Flow Margin of 10.58%. In addition the company used 19.58bn on investing activities and also paid 19.46bn in financing cash flows.
| Cash flow per share | 239.89 |
|---|---|
| Price/Cash flow per share | 24.06 |
| Book value per share | 2,753.51 |
|---|---|
| Tangible book value per share | 2,490.64 |
More ▼
Balance sheet in JPYView more
| Current ratio | 3.20 |
|---|---|
| Quick ratio | 2.45 |
| Total debt/total equity | 0.0047 |
|---|---|
| Total debt/total capital | 0.0047 |
More ▼
Growth rates in JPY
SmartText is unavailable
| Div yield(5 year avg) | 0.91% |
|---|---|
| Div growth rate (5 year) | 8.88% |
| Payout ratio (TTM) | 73.71% |
| EPS growth(5 years) | 3.30 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -50.54 |
More ▼
